[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oligo-metastatic-prostate-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oligo-metastatic-prostate-carcinoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,56],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100642127","mr-guided-single-fraction-sbrt-for-nodal-oligorecurrent-prostate-cancer-pinpoint-100642127",false,"NCT07635108","MR-guided Single-fraction SBRT for Nodal Oligorecurrent Prostate Cancer (PINPOINT)","Improved MR-Guided Single-fraction Stereotactic Sblative Radiotherapy in Pelvic and Abdominal Nodal Oliorecurrent Prostate Cancer","PINPOINT","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Signed informed consent\n* Histologically proven initial diagnosis of adenocarcinoma of the prostate\n* ECOG performance status 0-2\n* Biochemical recurrence after curatively intended local treatment (radical prostatectomy and\u002For radiotherapy), with PSMA-PET\u002FCT-verified nodal relapse in the pelvis or abdomen\n* Any additional sites of disease beyond the protocol-specified target lymph nodes must be considered suitable for ablative treatment\n* Life expectancy \\> 6 months\n* Lymph node size ≤ 2 cm\n\nExclusion Criteria:\n\n* Medical contraindications to MRI\n* Inability to tolerate the physical set-up required for SABR\n* Overlap between prior radiation fields and the current target area leading to high risk of clinically significant normal-tissue injury\n* Contraindications to pelvic radiotherapy (chronic pelvic inflammatory bowel disease)\n* Uncontrolled intercurrent illness","MALE","18 Years",{"count":20,"type":21},48,"ESTIMATED","INTERVENTIONAL",[24],"NA","This single-arm phase 2 trial investigates whether a single high-dose radiotherapy treatment can safely treat men whose prostate cancer has come back in a small number of lymph nodes in the pelvis or abdomen after curative treatment. Participants receive one fraction of 24 Gy delivered with MR-guided stereotactic body radiotherapy (SBRT), which uses MRI to visualise the tumour and surrounding organs during treatment. The main goal is to assess safety (severe side effects). The trial also evaluates local tumour control, longer-term side effects, time until hormone (androgen deprivation) therapy is needed, survival, and quality of life. The trial aims to enrol 48 patients.",[27,28,29,30],"Prostate Cancer","Oligo-metastatic Prostate Carcinoma","Oligometastatic Cancer","Nodal Oligorecurrent Prostate Cancer",[32,33,34,35,36,37,38,39,40,41,42],"Single-fraction SBRT","Nodal oligorecurrent prostate cancer","MR-guided SBRT","MR-Linac","Stereotactic body radiotherapy","Stereotactic ablative radiotherapy","Single-fraction radiotherapy","Oligometastasis \u002F oligorecurrence","Metastasis-directed therapy","PSMA-PET\u002FCT","Lymph node metastasis","NOT_YET_RECRUITING","2026-06-11",{"date":46,"type":47},"2026-06-15","ACTUAL",{"date":49,"type":21},"2026-06-01",{"date":51,"type":21},"2035-09",{"name":53,"class":54},"Odense University Hospital","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":55},"100531329","radiotherapy-for-prostate-and-oligo-metastatic-lesions-in-patients-with-low-burden-oligo-metastatic-prostate-cancer-100531329","NCT06198387","Radiotherapy for Prostate and Oligo-metastatic Lesions in Patients With Low-burden Oligo-metastatic Prostate Cancer","Efficacy and Safety of Radiotherapy for Prostate and Oligo-metastatic Lesions in Patients With Low-burden Oligo-metastatic Prostate Cancer: An Open, Exploratory Pilot Clinical Trial","Inclusion Criteria:\n\n* Aged 18 years or over at the time of registration\n* Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2;\n* Histologically confirmed prostate adenocarcinoma via prostate biopsy;\n* Assessment conducted via single-photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), and Ga-68 prostate-specific membrane antigen (PSMA) positron emission tomography\u002Fcomputed tomography(PET\u002FCT), revealing oligo-metastasis (involving \\\u003C 4 metastatic lesions in non-pelvic lymph nodes and bones) with or without pelvic lymph node involvement;\n* Expected survival duration \\>2 years.\n* The willingness of patients to voluntarily accept the experimental research protocol after being informed of existing treatment options.\n\nExclusion Criteria:\n\n* Any previous or ongoing treatment for prostate cancer, including radiotherapy, chemotherapy, focal treatment, etc.\n* Pathology indicating small-cell or neuroendocrine tumor components;\n* Patients with visceral metastases, or ≥4 metastases;\n* Patients with concurrent malignancies or those in an acute infection period or severe infection state; patients positive for Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), and\u002For syphilis (Treponema pallidum)\n* Severe or active systemic comorbidities that, in the investigator's judgment, might interfere with the treatment, evaluation, and compliance of this trial, including severe conditions affecting respiratory, circulatory, nervous, mental, digestive, endocrine, immune, urological, and other systems;\n* Individuals with contraindications related to radiation therapy may present heightened risks of treatment-related complications.\n* Patients participating in other clinical trials;\n* Patients unsuitable for participation in this clinical trial as per the judgement of the investigator.","75 Years",{"count":65,"type":21},30,[24],"The existing large prospective study demonstrates the benefits of primary radiotherapy in patients with low-volume oligo-metastatic prostate cancer (OMPC), and there is also more evidence of the benefits of local metastasis-directed therapy (MDT) for metastatic lesions. But there is no results from prospective study to demonstrate the efficacy of radiotherapy for prostate and oligo-metastases. Therefore, the aim of the protocol is to illustrate the efficacy of radiotherapy for prostate and oligo-metastatic lesions in patients with de novo OMPC.",[28],"2024-01-08",{"date":71,"type":47},"2024-01-10",{"date":73,"type":21},"2024-01-01",{"date":75,"type":21},"2028-09-01",{"name":77,"class":54},"Changhai Hospital"]